Three researchers at Massachusetts General Hospital (MGH) have received 2025 MGH ALS Young Investigator Awards for their research on genetic abnormalities, faulty energy systems, and why some nerve cells are more susceptible to damage than others in amyotrophic lateral sclerosis (ALS). The awards announced by the Sean M.
Young investigators receive MGH awards for ALS research
I keep playing a new song by Bon Iver. Once my husband, Todd, who has ALS, is set up on his computer after breakfast, I turn my attention to household chores until he needs my help again. My new find, “There’s a Rhythmn” [sic], has a reflective,…
Clene Nanomedicine is on track to seek accelerated approval of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS) by the end of the year, backed by neurofilament light chain (NfL) biomarker data from its expanded access program (EAP). Those analyses, which are intended to address a recommendation…
Neurosense Therapeutics said it’s scaled production of PrimeC, its oral therapy for amyotrophic lateral sclerosis (ALS), to commercial levels as it awaits regulatory approval to launch the medication in Canada. “This manufacturing milestone represents a critical leap forward in our commercialization roadmap,” Alon Ben-Noon, CEO of Neurosense, said in…
When my doctor told me that I had ALS, my reaction was like that of most newly diagnosed ALS patients. I felt a jumble of emotions and desperately wanted to let my friends and family know — but something held me back. Deep down I knew that when I…
Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly to develop and market ATLX-1282, a therapy candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. ATLX-1282 was developed using Alchemab’s platform, which uses machine learning and artificial intelligence (AI) to identify potential therapeutic targets for diseases…
Crunch Fitness will host a nationwide fundraising event to support Augie’s Quest to Cure ALS, an organization dedicated to funding innovative research, help develop treatments, and raise awareness of amyotrophic lateral sclerosis (ALS). Both Crunch members and nonmembers may take part at Crunch locations nationwide on May…
Implanting a sensor in a region of the brain that helps to control speech was shown in a U.S. study to not only decode the intended speech of a man with amyotrophic lateral sclerosis (ALS), but also to help this patient control a computer mouse. According to the researchers,…
My husband, Todd, and I work New York Times puzzles while we eat breakfast. Because Todd is paralyzed due to ALS, I feed him. We start with the Spelling Bee puzzle, which offers seven letters for you to make words with. There is always at least one word that…
Note: This story was updated May 13, 2025, to correct information about the company’s clinical trials. Spinogenix has received clearance from the U.S. Food and Drug Administration (FDA) to launch an expanded access program (EAP) for SPG302, its oral treatment for amyotrophic lateral sclerosis (ALS). EAPs, also known…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients